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Sir,
The study reported by Anderson et al (2000) in the August issue of
the BJC demonstrated a sustained improvement in symptom score
with corresponding improvement in QOL, when gemcitabine
(GC) was combined with best supportive care (BSC) vs BSC alone
in advanced NSCLC. Although GC produced an objective
response rate of 19%, with fewer patients requiring radiotherapy
(RT); and the time to RT salvage was longer with GC, there was no
difference in survival. While this study demonstrates once again
that patients’ symptoms and QOL do benefit from palliative
chemotherapy in advanced NSCLC, it does not eliminate one
important factor: the placebo effect associated with receiving
intravenous chemotherapy. 
It is common experience that patients’ expectations from
chemotherapy are greater than those of oncology professionals,
and therefore patients are more willing to undergo chemotherapy
even for small gain (Slevin et al, 1990). The very act of receiving
anticancer therapy gives patients a sense of optimism associated
with the perception that ‘something active is being done’ and that
they are not just ‘wasting away, waiting for the inevitable’. These
factors can be very powerful psychological stimuli which lead
patients to under-report symptoms either because they truly feel
better (placebo effect) or because of underlying fear that reporting
toxicity or symptomatic deterioration may lead to early cessation
of the treatment. 
Where the margin of benefit is so narrow, as in the case of this
study of single agent GC in NSCLC, we feel that blinded
placebo control trials are required to address the true benefit of
cytotoxic chemotherapy in terms of symptomatic improvement
and QOL. 
De Deyn and D’Hooge (1996), in debating the ethical issues
around placebo-controlled trials stated that for such studies to be
considered ethical, it was important that no adequate therapy for
the disease should exist and/or the presumed active treatment
should have side effects. One realizes that the scenario reported by
Anderson et al in their study fits De Deyn’s criterion rather well. 
While we may debate what constitutes an acceptable placebo in
such a study, an appropriate ‘placebo’ may be the same agent
given at a sub-therapeutic dose. The placebo arm would then
require the same degree of monitoring as the treatment arm in
order to confirm that no biological effect is observed on marrow,
renal and hepatic function. Only then can we truly evaluate the
effect of therapeutic doses of any chemotherapeutic agent on
symptoms and QOL, free from observer and patient bias as long as
the study remains blinded. And if such a study were to demon-
strate equivalence in terms of symptom and QOL benefit, it would
have a significant impact on our interpretation of similar studies
where chemotherapy with BSC have been compared to BSC alone.
Maybe we should use the window of opportunity provided by
advanced NSCLC to set up such a study before the opportunity is
lost for good. 
D Farrugia
Consultant Medical Oncologist,
Cheltenham General Hospital,
Sandford Road,
Cheltenham, GL53 7AN, UK
R Lewis
Consultant Respiratory Physician,
Worcester Royal Infirmary,
Castle Street Branch,
Worcester, WR1 3AS 
REFERENCES 
Anderson H (2000) Gemcitabine plus best supportive care (BSC) vs BSC in
inoperable non-small cell lung cancer – a randomized trial with quality of life
as the primary outcome. Br J Cancer 83: 447–453,
doi: 10.1054/bjoc.2000.1307 
De Deyn P and D’Hooge R (1996) Placebos in clinical practice and research. J Med
Ethics 22: 140–146 
Slevin M (1990) Attitudes to chemotherapy: comparing views of patients with cancer
with those of doctors, nurses and general public. Br Med J 300: 1458–1460
Letters to the Editor 
Chemotherapy and quality of life in advanced NSCLC 
137
British Journal of Cancer (2001) 85(1), 137–140
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1851, available online at http://www.idealibrary.com on  http://www.bjcancer.com
Sir,
There are now 5 recent randomized trials assessing the value of
chemotherapy versus best supportive care in chemotherapy naive
patients with locally advanced or metastatic non-small cell lung
cancer. The chemotherapy regimens were single agent gemc-
itabine, paclitaxel, vinorelbine in a selected elderly population, the
combination mitomycin C, ifosfamide and cisplatin (MIC) and
single agent docetaxel (Cullen et al, 1999; the Elderly Lung
Cancer Vinorelbine Italian Study Group, 1999; Anderson et al,
2000; Ranson et al, 2000; Roszkowski et al, 2000). There was
evidence of median or 1 year survival advantage in all studies
except the gemcitabine study. However, we note that in the gemcit-
abine study more patients were WHO performance status 2 (72%)
than in the other studies (18–32%), probably because asympto-
matic patients were not eligible for entry into our study. 
All of the studies have assessed quality of life – a difficult area
of research, but all studies have shown some quality of life bene-
fits with chemotherapy. In addition, our study was designed with
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doi: 10.1054/ bjoc.2001.1852, available online at http://www.idealibrary.com on quality of life as a primary outcome and criteria for sustained
improvement in quality of life were established prior to data
analysis, emphasizing the validity of our reported findings. 
A recent report from the ECOG group (study E1594) showed
that modern combination chemotherapies produced equivalent
survival at one year (31–36%) for platinum combinations with
taxol, gemcitabine, and docetaxel (Schiller et al, 2000). This one-
year survival is better than the approximately 15% reported in the
best supportive care groups in meta-analysis (Souquet et al, 1993;
Marino et al, 1994; NSCLCCG, 1995). The ECOG group stopped
treating WHO performance status 2 patients because of their
poorer outcome and less than 7% patients in their study were in
this category. This patient group needs to be the subject of further
data analysis. 
Perhaps we can now formulate treatment plans based on stage
and performance status. Most oncologists treating patients with
inoperable non-small cell lung cancer would accept a cisplatin-
based regimen as standard therapy for metastatic disease espe-
cially for performance status 0 and 1 patients. For these small
survival advantages quality of life improvements are important.
Oncologists stop chemotherapy after 2 courses if the patient has
not benefited. 
We understand the authors may question the value of a new
agent used alone in the symptom management of patients with
non-small cell lung cancer. Patients entered into our trial should
have received the best symptomatic therapy available. The authors
question if a placebo effect with gemcitabine improved the
patients’ quality of life but provide no evidence to support this
suggestion, nor do they support their contention that ‘powerful
psychological stimuli lead patients to under-report symptoms’
whilst on chemotherapy. In both arms of our study improvement
and deterioration in symptoms occurred but there was an overall
advantage for patients treated with chemotherapy. 
Placebo studies in cancer chemotherapy are hard to justify for
the following reasons: 
1. Asking a patient to attend for regular intravenous placebo
injections is very problematic and considered unethical by
some people. 
2. The placebo cannot be blinded as the professional staff will
know which patients are on the active drug because of side
effects. 
3. The authors’ suggestion about using sub-therapeutic doses of
active drugs as a placebo is unethical as toxicity would occur.
Phase I trials are conducted to determine the recommended
treatment dose for a given schedule dependent upon the
maximum tolerated dose of drug allowing for toxicity. This
dose is then used in phase II trials to confirm efficacy. 
4. Professionals who regularly treat lung cancer would find it
unethical to conduct a placebo-based study because of the
published benefits with chemotherapy either in combination or
as single agent therapy. 
5. In trials patients who have unexpected side effects or 
progression stop therapy. In this trial the median number of
cycles was 3 (i.e. 3 months). The benefits on gemcitabine vs
BSC on quality of life were maintained at 4 months. 
6. In this trial one may have expected a placebo response to
include relief of dyspnoea but this symptom was better 
palliated by BSC at the 2 month assessment. 
7. Randomization should reduce the tendency for a ‘placebo
response’ with chemotherapy (if such a response exists), since
patients with strong expectations or beliefs about the value of
chemotherapy would have refused randomization. 
8. A recent study assessing the influence of pre-treatment 
optimism on quality of life and progression-free survival after
radical radiotherapy for lung cancer has shown no significant
difference in 2 year survival (Ball et al, 2000). i.e. ‘Patient
optimism is not enough’. 
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